Search

Meet our new member Cencora Pharmalex. We spoke with Gonzalo Casino Fernández, Director General Cencora Pharmalex Iberia.

Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects

VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025

The public research institutes, together with the units and groups of the University of Barcelona (UB) present at the Barcelona Science Park (PCB-UB), have reached a new funding record in 2024. This

The investment will enable Qida to boost growth, technological innovation, and the attraction of top talent, with the goal of reaching more than 100,000 people served and quadrupling sales within

Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCD

BCN HEALTH has published in the Journal of Medical Economics a study analyzing the incidence, management, and associated costs of chronic kidney disease (CKD) in Spain between 2011 and 2017. Based on

The company expects to close the year with sales exceeding €50 million and an EBITDA above €20 million

AptaTargets signed in May 2025 a licensing agreement with Merck for the clinical development and global commercialisation of ApTOLL, an aptamer with neuroprotective effect for the treatment of

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: